News archives

Successful completion of phase Ib

20 October 2003

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the successful completion of a phase Ib clinical study of its orally active synthetic neuroprotective and neuroregenerative product, PYM50028, which is under development as a treatment for a range of neurological disorders, including Alzheimer’s and Parkinson’s diseases (programmes P58 and P63, respectively).

Pfizer returns rights of P57

30 July 2003

Phytopharm announced today that it has received notice from Pfizer that it will discontinue clinical development of P57 for the treatment of obesity and return the rights to the company. P57 is a novel appetite suppressant that has been shown to reduce caloric intake in overweight subjects, as announced by Phytopharm in December 2001.

Appointment of Finance Director

8 July 2003

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”), the Botanical pharmaceutical company, announces today that Dr Wang Chong has been appointed Chief Financial Officer with immediate effect. Dr Chong, who was appointed to Phytopharm as Commercial Director in April 2003, replaces Dr Simon Loach who is leaving the company to pursue other interests.

Collaboration with OPTIMA (University of Oxford)

23 June 2003

Phytopharm plc (PYM: London Stock Exchange) announces today that it has entered into an agreement with the Oxford Project to Investigate Memory and Ageing (OPTIMA) regarding the clinical development of PYM50028, its novel oral treatment for dementias including Alzheimer’s disease. Under the joint leadership of Professor David Smith (Project Leader, OPTIMA) and Professor Robin Jacoby (Principal Investigator), OPTIMA will enrol patients with memory impairment into the Phase II proof of principle study, which is expected to commence dosing in Q4 2003.

Successful completion phase I

20 May 2003

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the successful completion of a phase I clinical study to evaluate the safety, tolerability and pharmacokinetic profile of its orally active synthetic neuroprotective and neuroregenerative product, PYM50028, which is under development as a treatment for a series of neurological disorders, including Parkinson’s disease (programme P63).

Collaboration with Yamanouchi

1 May 2003

Phytopharm plc (PYM: London Stock Exchange) announces today that it has signed a licensing agreement with the leading Japanese pharmaceutical company, Yamanouchi Pharmaceutical Co., Ltd., for the development and commercialisation of PYM50028, a synthetic neuroprotective and neuroregenerative agent that has been selected from the library of compounds within the company’s neurodegeneration platform. The initial target indication licensed by Yamanouchi is Alzheimer’s disease. Yamanouchi also receives options to develop the product for additional indications, as detailed below.

Interim results for the period to 28 February 2003

1 May 2003

Phytopharm plc today announces interim results for the six-month period to 28 February 2003.

Appointment of Commercial Director

14 April 2003

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today that Dr Wang Chong has joined the company’s senior management team as Commercial Director. Dr Chong will be responsible for the overall management of in- and out-licensing and commercial development of Phytopharm’s product pipeline.

Update on development programme for Appetite Suppressant P57

12 March 2003

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today that it has received the first six monthly progress report from Pfizer Inc (”Pfizer”) concerning the ongoing development of its appetite suppressant P57. This follows the announcement in July 2002 that Pfizer was taking responsibility for the development of the product, under the terms of the Licence and Royalty agreement entered between Pfizer and Phytopharm in August 1998. P57 is a novel appetite suppressant that has been shown to reduce caloric intake in overweight subjects, as announced by Phytopharm in December 2001.

Appointment of Broker and Joint Financial Adviser

26 February 2003

Phytopharm plc, the UK-based, LSE listed botanical pharmaceuticals company, announces today the appointment of Nomura International plc as its broker and joint financial adviser, with immediate effect.